A new cannabinoid that raises new possibilities

15.04.21

The world of cannabinoids is experiencing a revolution with the discovery of new molecules with still unknown potential. This is the case of the discovery of cannabidiforol (CBDP), a cannabinoid homologous to CBD and that may be the protagonist of the new scientific studies carried out on the plant.

This discovery is very recent and was more or less fortuitous. In this way, Italian researchers have been in charge of locating this cannabinoid in the composition of plants while trying to define the profile of the phytocannabinoids present in marijuana.

The discovery has not come alone, since this same group of scientists has managed to locate another new cannabinoid, known as THCP, which is in turn homologous to THC, the psychoactive cannabinoid found in Cannabis plants. That is why it is possible to speak of a new double discovery of which there is still much to be investigated.

In today’s article the keys to the discovery of this new cannabinoid, CBDP, will be given and what science says about this discovery for the time being will also be addressed. For this, the known characteristics of the CBDP are shelled, in addition to the potential uses that science can see in it.

CBDP: the new phytocannabinoid discovered by science

CBDP or cannabidiforol is a phytocannabinoid. Phytocannabinoids are cannabinoids that they occur naturally in the cannabis plant. Classic cannabinoids are formed through the decarboxylation of their respective 2-carboxylic acids (2-COOH), a process that is catalyzed by heat, light, or alkaline conditions.

In other words, CBDP is a new cannabinoid present in Cannabis plants about which there is still not the same information that can be had in the case of CBD or THC. There are more than 150 phytocannabinoids discovered to this day, although the fact that they have been discovered does not imply that there is much information about each of them. Thus, only a small number of these 150 cannabinoids have been studied and synthesized so far.

Some of the most avant-garde techniques that science has for this purpose have been used for the discovery of CBDP. This is the case of the state-of-the-art spectrometry, which consists of an in-depth analysis that brings to light those compounds that have not yet been identified in the marijuana plant.

The main difference of CBDP with CBD is that the first of them is served in its structure of a elongated seven-link side chain, instead of the 5 links that CBD has. But … Why is this revolutionary? Because natural cannabinoids with more than five links in this side chain have not yet been detected in cannabis.

However, this novel fact affects CBDP differently than THCP. Thus, this group of Italian scientists has shown that the elongated side chain of THCP appears to have an even stronger affinity for the CB1 receptor than normal THC, suggesting that it can perform its function more potently.

When the researchers verified the binding affinity of THCP against the human CB1 and CB2 receptors, they found that the THCP was 33 times more active than THC regular at the CB1 receptor and 5 to 10 times more active than regular THC at the CB2 receptor.

However, in the case of CBDP, the story is different, since because CBD has a poor binding affinity for CB1 and CB2 receptors, it is possible that a longer side chain is unlikely to help CBDP bind more effectively to receptors in the body.

However, as the researchers point out, science can hold big surprises, and Future research may show that CBDP has hidden qualities therapeutic or potency that we are currently unaware of. At the moment nothing can be affirmed, and we can only wait for the results of the study.

Can the use of CBDP be legal?

It is difficult a priori to determine if this new group of Cannabinoids such as CBDP could become regularized in countries like Spain. Yes, analogies can be made with CBD. The fact is that CBD is not registered as a food supplement by the Spanish Agency for Medicines and Health Products.

Therefore, all products with CBD content cannot be classified as dietary supplements. This maybe can be extended to CBDP when there is more information about this cannabinoid, and it does not mean that CBD or CBDP are illegal, but that it is not allowed to be distributed as a product suitable for human consumption and is intended exclusively for industrial use.

That cane hinder the study of new cannabinoids such as CBDP in countries like Spain, which in many cases will have to be cultivated for industrial purposes in order to later be studied in depth. In countries where the legislation is more lax, such as the United States and the Netherlands, it is possible that more detailed studies can be carried out on these compounds, in addition to the fact that the population comes to make therapeutic or recreational use of CBDP earlier than in other countries .

The discovery of these new cannabinoids it opens up a very hopeful and uncertain outlook. Future research will be in charge of determining the possible uses that these cannabinoids may have. Measuring the risks and potential therapeutic uses of these phytocannabinoids requires many laboratory tests.

Furthermore, the discovery of both CBDP as of THCP is important when underlining the evolution that the Cannabis industry is experiencing in recent years. It is not only investigated in obtaining new varieties with active cannabinoids and better organoleptic properties, but also It is also committed to research and development to obtain new cannabinoids that can bring rigor to scientific studies on Cannabis in therapeutic settings.

If you enjoyed this article, you can follow up with interesting readings like Trichome Research Initiative and Aging Marijuana Resin and THCP: The Newly Discovered Cannabinoid by Science.

Author: Igor Vieira

Graduate in Molecular Biology, content manager and store manager in Natural Experience. Living life, talking about Cannabis Sativa, father. Collegiate number is 20787-X Linkedin Bio See all posts by Igor Vieira

Related words: